BUSINESS

Reata Developing Sakigake Designated DKD Drug for Alport Syndrome in Japan

December 28, 2018
Reata Pharmaceuticals is developing bardoxolone in Japan as a treatment for Alport syndrome, a form of hereditary glomerulonephritis, Jiho has learned. If approved, the drug, which has been designated for the sakigake fast-track review for diabetic kidney disease (DKD), is likely…

To read the full story

BUSINESS

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…